BACKGROUND: Transforming growth factor beta-1 (TGF-β1) participation in breast cancer development and metastasis is well-established, however, the clinical meaning of its circulating levels in women with breast cancer is poorly understood. AIM: To characterize the levels of TGF-β1 in plasma from women with breast cancer and to associate them with the main clinical factors associated with disease prognosis. PATIENTS AND METHODS: TGF-β1 levels were measured by Enzyme-linked immunoassay (ELISA). Clinicopathological data were also assessed. RESULTS: Women bearing triple-negative tumors presented significantly reduced levels of this cytokine when compared to the other subtypes (p=0.0338). Patients with metastases exhibited lower levels of TGF-β1 than the non-metastatic cohort (p=0.0442). Patients with early-onset disease had the highest plasma TGF-β1 levels (p=0.0036). Doxorubicin chemotherapy induced a reduction in TGF-β1 level, promptly after drug infusion (p=0.0494). Patients with TGF-β1 levels lower than 20 pg/ml exhibited a tendency to have a reduced overall survival in a 40-month follow-up. CONCLUSION: Lower levels of circulating TGF-β1 are associated with a poor disease prognosis.
BACKGROUND:Transforming growth factor beta-1 (TGF-β1) participation in breast cancer development and metastasis is well-established, however, the clinical meaning of its circulating levels in women with breast cancer is poorly understood. AIM: To characterize the levels of TGF-β1 in plasma from women with breast cancer and to associate them with the main clinical factors associated with disease prognosis. PATIENTS AND METHODS: TGF-β1 levels were measured by Enzyme-linked immunoassay (ELISA). Clinicopathological data were also assessed. RESULTS:Women bearing triple-negative tumors presented significantly reduced levels of this cytokine when compared to the other subtypes (p=0.0338). Patients with metastases exhibited lower levels of TGF-β1 than the non-metastatic cohort (p=0.0442). Patients with early-onset disease had the highest plasma TGF-β1 levels (p=0.0036). Doxorubicin chemotherapy induced a reduction in TGF-β1 level, promptly after drug infusion (p=0.0494). Patients with TGF-β1 levels lower than 20 pg/ml exhibited a tendency to have a reduced overall survival in a 40-month follow-up. CONCLUSION: Lower levels of circulating TGF-β1 are associated with a poor disease prognosis.
Authors: Adma Poliana Cecilio; Erika Tomie Takakura; Jaqueline Janaina Jumes; Jeane Wilhelm Dos Santos; Ana Cristina Herrera; Vanessa Jacob Victorino; Carolina Panis Journal: Breast Cancer (Dove Med Press) Date: 2015-01-29
Authors: Consolación Melguizo; Laura Cabeza; Jose Prados; Raúl Ortiz; Octavio Caba; Ana R Rama; Ángel V Delgado; José L Arias Journal: Drug Des Devel Ther Date: 2015-12-14 Impact factor: 4.162
Authors: Eman Radwan; Asmaa S Shaltout; Shima Gafar Mansor; Engy A Shafik; Wael A Abbas; Mahmoud Refaat Shehata; Maha Ali Journal: Mol Biol Rep Date: 2021-06-16 Impact factor: 2.316